Development of monolithic matrix type transdermal patches containing cinnarizine: Physical characterization and permeation studies
Braz. J. Pharm. Sci. (Online)
; 58: e19859, 2022. tab, graf
Article
em En
| LILACS
| ID: biblio-1383996
Biblioteca responsável:
BR40.1
Localização: BR40.1
ABSTRACT
To overcome the problems associated with bioavailability and systemic side effects of the drug by oral administration, monolithic matrix type transdermal patches containing cinnarizine (CNZ) were developed. For this purpose, films based on hydroxypropyl methylcellulose and polyvinylpyrrolidone as matrix-forming polymers were designed. Physical characteristics of transdermal films and drug-excipient compatibility were investigated. Factors affecting in vitro drug release and ex vivo skin penetration and permeation of the drug were studied. It was confirmed that films displayed sufficient flexibility and mechanical strength for application onto the skin for a long time period. Ex vivo penetration experiments gave satisfactory results for transdermal drug delivery through rat skin. The parameters determining good skin penetration were also evaluated. The highest drug permeation rate was obtained with incorporation of Transcutol® (0.102 mg/cm2/h) into the base CNZ formulation, followed by propylene glycol (0.063 mg/cm2/h), menthol (0.045 mg/cm2/h), and glycerin (0.021 mg/cm2/h) as penetration enhancers (p < 0.05). As a result, the developed transdermal patches of CNZ may introduce an alternative treatment for various conditions and diseases such as idiopathic urticarial vasculitis, Ménière's disease, motion sickness, nausea, and vertigo. Thus, the risk of systemic side effects caused by the drug can be reduced or eliminated
Palavras-chave
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Administração Oral
/
Cinarizina
/
Agonistas dos Receptores Histamínicos
/
Antagonistas Colinérgicos
/
Anestésicos
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article